Cardiovascular diseases (ischaemic heart disease and cerebrovascular disease) are the leading causes of death, not just in Spain but also all over the world (Data source: Defunciones según la Causa de Muerte. Año 2011.Instituto Nacional de Estadística: 2013). The prevalence of these diseases, far from diminishing, keeps on growing due to the progressive ageing of the population and the increase in the diabetes and obesity numbers, two main pathologies which favor heart diseases.

Prevention is a big challenge for medical science. Hence, the research group of the Lipids Unit at Reina Sofía University Hospital in Córdoba and member of the Nutrigenomics. Metabolic Syndrome research group of IMIBIC is developing a research in order to demonstrate if diets affect the risk of suffering clinical manifestations on people who have already been hit by cardiovascular disease. This is, precisely, the main objective of the study CORDIOPREV, which consists in a diet intervention project where 1004 patients affected by previous cardiovascular disease follow two different health diet programs so as to find out whether they are equally beneficial for them.

These two models are:

  • Fat-low: they do not exceed 28% of the total calorie input of fat (12% of Monounsaturated Fatty Acids).
  • Mediterranean: with a calorie input of fat of 34% (22% of Monounsaturated Fatty Acids) essentially at the expense of olive oil.

The estimated length of the study is 5 years. It was started in november 2009 and it’s currently in process.

The research group of CORDIOPREV is firmly committed to it and aims to demonstrate the beneficial effect of these two diet models on the cardiovascular field, helping to prevent new events for patients who have already had an acute myocardial infarction or an angina pectoris. Up to now, this is the first study in the world which addresses this purpose as a main goal in patients attacked by previous heart disease.

It is very important to note that its development would not be possible without the invaluable collaboration of the patients and their families. Accordingly, we want to acknowledge the support of the different entities financing the study, especially Fundación Patrimonio Comunal Olivarero, which wholeheartedly endorses CORDIOPREV.

We are 1002 participants